Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
Posted on: Wednesday, 28 November 2007, 06:00 CST
EMERYVILLE, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc (NTI (TM)) announced today that Warren Wasiewski, M.D. was appointed Chief Medical Officer, effective as of November 26, 2007.
Dr. Wasiewski joined NTI in February 2007 as Vice President, Clinical Programs with primary responsibility for running the clinical trial program for Viprinex(TM), NTI's drug candidate for acute ischemic stroke that is currently in two Phase 3 clinical trials. Dr. Wasiewski is a Board Certified Pediatric Neurologist with an extensive clinical career. Prior to joining NTI, he worked at AstraZeneca where he was Sr. Medical Director of clinical research CNS/Emerging Products. At AstraZeneca, Dr. Wasiewski had responsibility for running the global SAINT trials for AstraZeneca's neuroprotectant drug candidate.
Dr. Wasiewski holds a Bachelor of Arts degree in Biology Cum Laude from Rutgers College, a Masters of Science degree in Biochemistry from State University of New York Downstate Medical Center, and a Doctorate of Medicine from State University of New York, at Buffalo.
About Neurobiological Technologies, Inc.
NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.
Neurobiological Technologies, Inc.
CONTACT: Craig Carlson of Neurobiological Technologies, Inc.,+1-510-595-6000, ccarlson@ntii.com
Source: PRNewswire-FirstCall
Related Articles
- Elekta and RAD Technology Medical Systems Team Up to Place First Temporary Modular Radiation Oncology Center in Northern California
- KaloBios Completes Patient Dosing in Its U.S. Phase 1 Trial of Its Third Drug Candidate, KB003
- BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known As Karenitecin(R)
- Alfacell Completes Non-Clinical Section of Rolling NDA for Lead Anticancer Drug ONCONASE(R)
- Positive First Human Trial for Siga Smallpox Drug
- Biovail to Promote AstraZeneca Drug in US
- Positive Trial for MGI Pharma Drug in MDS
- Corgentech Presents Clinical Data From Phase 1/2 Trial of Avrina(TM), Drug Candidate for Eczema
- Corgentech Reports Clinical Data From Phase 1/2 Trials of Avrina(TM), Drug Candidate for Eczema
- Metabolic Pharmaceuticals Initiates Recruitment for Phase II-B Clinical Trial of AOD9604 Obesity Drug
 |
 |
User Comments (0)
RSS Feeds